Department of Haematology, Peter MacCallum Cancer Centre, St Andrew's Place, East Melbourne, Victoria, Australia.
Clin Cancer Res. 2012 Jul 1;18(13):3509-15. doi: 10.1158/1078-0432.CCR-11-3144. Epub 2012 Apr 24.
Cutaneous T-cell lymphomas (CTCL) are relatively rare lymphomas with an annual incidence of approximately 0.2 to 0.8/100,000 and comprise a variety of clinical entities; mycosis fungoides or its leukemic variant Sezary syndrome account for the majority of cases. Advanced-stage disease is typically treated with bexarotene (a retinoid), interferon, or conventional chemotherapeutic agents, but relapses are inevitable. Histone deacetylase inhibitors, which modify the epigenome, are an attractive addition to the armamentarium. On the basis of 2 large phase II studies, the U.S. Food and Drug Administration approved intravenous romidepsin for patients with relapsed and/or refractory CTCL. Romidepsin provides a subset of patients with an opportunity for prolonged clinical responses with a tolerable side effect profile.
皮肤 T 细胞淋巴瘤（CTCL）是一种相对罕见的淋巴瘤，年发病率约为 0.2 至 0.8/10 万，包括多种临床实体；蕈样真菌病或其白血病变体 Sezary 综合征占大多数病例。晚期疾病通常用贝沙罗汀（一种类视黄醇）、干扰素或常规化疗药物治疗，但复发是不可避免的。组蛋白去乙酰化酶抑制剂可修饰表观基因组，是治疗方法的一个有吸引力的补充。基于两项大型 II 期研究，美国食品和药物管理局批准静脉用罗米地辛用于治疗复发和/或难治性 CTCL 患者。罗米地辛为一部分患者提供了延长临床缓解期的机会，且具有可耐受的副作用谱。
